Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 18/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899400 | 0.77 | ADORA2A (0.32) | ADORA2AADORA2BADORA1 | |
| SCHEMBL28436816 | 0.75 | PDE10A (0.33) | ADORA2AADORA2BADORA1 | |
| SCHEMBL4440111 | 0.71 | MAPT (0.46) | — | |
| SCHEMBL28427170 | 0.70 | TLR8 (0.82) | TLR8 | |
| SCHEMBL11066175 | 0.67 | LTA4H (0.49) | ADORA2AADORA2BADORA1 | |
| SCHEMBL7071992 | 0.65 | PIK3CD (0.31) | — | |
| SCHEMBL1551877 | 0.62 | ADORA2A (0.42) | ADORA2AADORA2BADORA1 | |
| SCHEMBL15545185 | 0.62 | ADORA2A (0.42) | ADORA2AADORA2BADORA1 | |
| SCHEMBL8826186 | 0.62 | GPR39 (0.32) | — | |
| SCHEMBL6102228 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220393-A1 | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | SMITH LARRY J (US) | 2023-07-13 | — | — | US | claimed |
| US-20200362343-A1 | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | SMITH LARRY J (US) | 2020-11-19 | — | — | US | claimed |
| US-20190300878-A1 | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | SMITH LARRY J (US) | 2019-10-03 | — | — | US | claimed |
| US-20240218365-A1 | FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE | THE PROGERIA RESEARCH FOUNDATION, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4392558-A1 | ANTISENSE OLIGONUCLEOTIDES HAVING ONE OR MORE ABASIC UNITS | Sarepta Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4387676-A2 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | Sarepta Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024127026-A1 | MEMBRANE FILTRATION-ASSISTED SOLUTION PHASE OLIGONUCLEOTIDE SYNTHESIS | Exactmer Limited (GB) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024121373-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | PROQR THERAPEUTICS II B.V. (NL) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024115635-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF ALDEHYDE DEHYDROGENASE 2 DEFICIENCY | PROQR THERAPEUTICS II B.V. (NL) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024110565-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF HEREDITARY HFE-HEMOCHROMATOSIS | PROQR THERAPEUTICS II B.V. (NL) | 2024-05-30 | — | — | WO | disclosed |
| CN-118103384-A | Solution phase polymer synthesis | 艾克特姆有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20170051286-A1 | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | SMITH LARRY J (US) | 2017-02-23 | — | — | US | disclosed |
| WO-2016187425-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SAREPTA THERAPEUTICS, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016180784-A1 | IMPROVED TREATMENTS USING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II B.V. (NL) | 2016-11-17 | — | — | WO | disclosed |
| WO-2015168661-A1 | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | SMITH LARRY J (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20150291957-A1 | METHODS AND COMPOSITIONS TO PRODUCE ss-RNAi ACTIVITY WITH ENHANCED POTENCY | SMITH LARRY J (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150191725-A1 | Oligonucleotide for the Treatment of Muscular Dystrophy Patients | BIOMARIN TECHNOLOGIES B.V. (NL) | 2015-07-09 | — | — | US | disclosed |
| EP-2870246-A2 | OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS | Prosensa Technologies B.V. (NL) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014066915-A2 | METHODS AND COMPOSITIONS TO PRODUCE SS-RNAI ACTIVITY WITH ENHANCED POTENCY | SMITH LARRY J (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014007620-A2 | OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS | PROSENSA TECHNOLOGIES B.V. (NL) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218365-A1 | FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE | POLB, GBA1, POLN | TLR8 4266/4885ADORA2A 3016/4885ADORA2B 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.